Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the Quadra Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (≥4Th Line), Advanced, Recurrent High-Grade Serous Ovarian Cancer
AuthID
P-00V-T9P
P-00V-T9P